A post hoc analysis of data from the RENAAL and IDNT trials shows that a low-sodium diet can increase the efficacy of angiotensin-receptor blockers (ARBs) in patients with type 2 diabetic nephropathy. A comparison of the treatment effects of ARBs and non-renin–angiotensin–aldosterone-system (RAAS)-based antihypertensive therapy in subgroups based on sodium intake showed that the treatment effects of ARBs versus non-RAAS-based therapies on cardiovascular and renal end points were greater in patients with lower versus higher sodium intake.